Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there's no evidence of safety concerns linked to long-term use of the drug, researchers saySource: HealthDay
Related MedlinePlus Page: Chronic Myeloid Leukemia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 8, 2017 Category: Consumer Health News Source Type: news
Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
WEDNESDAY, March 8, 2017 -- The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment -- with no signs of additional safety risks, a new study finds.
Gleevec -- known generically as imatinib -- was hailed as a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 8, 2017 Category: Journals (General) Source Type: news
New England Journal of Medicine publishes long-term results of Gleevec ®
(Oregon Health& Science University) Today the New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. According to the National Cancer Institute, prior to Gleevec's 2001 FDA approval, fewer than one in three CML patients survived five years past diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 8, 2017 Category: Cancer & Oncology Source Type: news
Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there ' s no evidence of safety concerns linked to long - term use of the drug, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 7, 2017 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, News, Source Type: news
Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors
A substantial minority of patients with advanced gastrointestinal stromal tumors (GIST) treated with imatinib mesylate show long-term survival, according to a trial analysis presenting new molecular data.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 21, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Study shows strong long-term survival rates for patients with GIST
Nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years, a new report outlines. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2017 Category: Science Source Type: news
SWOG study shows strong long-term survival rates for patients with GIST
(SWOG) Researchers show that nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years. Results are published in JAMA Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2017 Category: Global & Universal Source Type: news
Adding Pioglitazone Could Improve Molecular Response in CML Patients
A small preliminary study showed that adding pioglitazone to imatinib therapy might have a favorable impact on residual disease in chronic myeloid leukemia, as measured by conversion to molecular response 4.5. (Source: CancerNetwork)
Source: CancerNetwork - January 5, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Natural Killer Cells Play Role in Ability of CML Patients to Discontinue TKIs
Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing therapy with imatinib. (Source: CancerNetwork)
Source: CancerNetwork - December 29, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Colombia cuts price of Novartis cancer drug by 44 percent
BOGOTA (Reuters) - Colombia's government has lowered the price of Novartis cancer drug imatinib by nearly half in a bid to cut healthcare costs after failed price negotiations with the Swiss company. (Source: Reuters: Health)
Source: Reuters: Health - December 21, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Retro Report: Lives and Profits in the Balance: The High Stakes of Medical Patents
Tensions inherent to drug pricing pit affordability against the need to recoup investment in research, raising questions about how much of the cost patients should have to bear. (Source: NYT Health)
Source: NYT Health - December 12, 2016 Category: Consumer Health News Authors: CLYDE HABERMAN Tags: Drugs (Pharmaceuticals) Inventions and Patents Prices (Fares, Fees and Rates) Bayh-Dole Act Novartis AG Gleevec Advertising and Marketing Source Type: news
Pfizer blood cancer drug tops standard therapy for untreated patients
(Reuters) - Pfizer Inc said on Monday its cancer drug, Bosulif, was found superior to Novartis AG's Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer characterized by abnormal white blood cells production. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Global Health: Summer Project Turns Into Leukemia Testing Breakthrough
What began as a student effort at a lab in Seattle produced a test for chronic myeloid leukemia that works with a few spots of dried blood on a paper card. (Source: NYT Health)
Source: NYT Health - November 28, 2016 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Tests (Medical) Drugs (Pharmaceuticals) Leukemia Third World and Developing Countries Novartis AG Africa Gleevec Source Type: news
Money in Medicine: Brian Druker on why he gets money from Gilead, not Gleevec
Dr. Brian Druker ’s name is practically synonymous with Gleevec, which is about as close as you can get to a miracle drug.
Yet Druker has never directly benefited from Gleevec, which has greatly expanded the life expectancy for those with chronic myeloid leukemia. Because he didn’t invent and patent the drug, h e receives no royalties.
He did give a couple of talks about it for drug maker Novartis, but then called it quits on those sorts of gigs.
“I decided it was not what I want to be doing,”… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 22, 2016 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news
Money in Medicine: Brian Druker on why he gets money from Gilead, not Gleevec
Dr. Brian Druker ’s name is practically synonymous with Gleevec, which is about as close as you can get to a miracle drug.
Yet Druker has never directly benefited from Gleevec, which has greatly expanded the life expectancy for those with chronic myeloid leukemia. Because he didn’t invent and patent the drug, h e receives no royalties.
He did give a couple of talks about it for drug maker Novartis, but then called it quits on those sorts of gigs.
“I decided it was not what I want to be doing,”… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 22, 2016 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news
